Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

Yun HD, Schirm DK, Felices M, Miller JS, Eckfeldt CE.

Blood Adv. 2019 Aug 27;3(16):2448-2452. doi: 10.1182/bloodadvances.2019000064. No abstract available.

2.

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Pomeroy EJ, Lee LA, Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE.

Oncogene. 2017 Jun 8;36(23):3263-3273. doi: 10.1038/onc.2016.471. Epub 2016 Dec 19.

3.

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, Waggie KS, Peffault de Latour R, Janin A, Curtsinger JM, Dillon SR, Miller JS, Socie G, Blazar BR.

Blood. 2012 Jan 12;119(2):619-28. doi: 10.1182/blood-2011-07-368027. Epub 2011 Nov 10.

4.

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR.

Sci Transl Med. 2011 May 18;3(83):83ra41. doi: 10.1126/scitranslmed.3001809.

5.

Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.

Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR.

Am J Transplant. 2011 Jun;11(6):1148-57. doi: 10.1111/j.1600-6143.2011.03558.x. Epub 2011 May 12.

Supplemental Content

Loading ...
Support Center